Ask an Expert
India’s pharmaceutical industry, the world’s largest producer of generic medicines, is at a turning point. Over the last decade, Indian pharma operations have grown at more than twice the global rate, driven by strong manufacturing infrastructure, improving quality standards, cost leadership, expanded capabilities across complex products, and resilient supply chains. India now hosts hundreds of FDA, WHO-GMP, and EDQM approved facilities and continues to benefit from structurally lower manufacturing costs compared to the US and Europe.
However, this momentum is facing new challenges. Internal pressures such as plateauing performance and rising quality expectations are converging with external disruptions including geopolitical uncertainty, sustainability demands, nearshoring trends, and rapid advances in digital technologies, automation, and new therapeutic modalities.
To unlock the next phase of growth, the industry must fundamentally rethink operations. The report outlines eight strategic priorities for the next decade. These include zero-error, smart quality systems; low-touch and autonomous manufacturing plants; smaller and modular manufacturing footprints; customer-centric operations to scale CDMO services; renewed enterprise-wide cost leadership; distributed global manufacturing networks; AI-driven autonomous supply planning; and green operations aligned with net-zero goals.
By executing these priorities, India’s pharma sector can move into a new S-curve of growth, strengthening global leadership while improving quality, resilience, sustainability, and innovation.
